Valuation: Control Bionics Limited

Market Cap 30.49M 21.23M 18.57M 17.14M 15.78M 29.75M 2.04B 205M 80.69M 1B 79.72M 77.97M 3.45B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.06M 18.43M 17.01M 15.66M 29.52M 2.03B 203M 80.06M 994M 79.1M 77.36M 3.42B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
1 day-1.43%
1 week-5.48%
Current month-6.76%
1 month-21.59%
3 months+9.52%
6 months-2.82%
Current year+13.11%
1 week 0.06
Extreme 0.065
0.08
1 month 0.06
Extreme 0.065
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%-5.48%+56.82%-18.82% 19.85M
-1.46%+0.58%+18.67%-22.19% 17.27B
-6.27%-7.01%-0.84%+86.72% 1.57B
-4.71%-4.87%-31.71%-79.21% 1.19B
-1.34%-5.93%-37.82%+13.91% 999M
-4.06%+2.84%-28.35%-52.18% 644M
-7.46%-4.05%-40.62%-56.91% 532M
-1.95%-4.52%+45.72%-53.63% 445M
-1.26%+0.64%-54.33%-58.41% 382M
+7.76%+6.36%-19.65%-21.95% 364M
Average -2.22%-1.75%-9.21%-26.27% 2.34B
Weighted average by Cap. -2.01%-0.35%+8.52%-19.04%

Financials

2024 2025
Net sales 5.35M 3.73M 3.26M 3.01M 2.77M 5.22M 359M 35.95M 14.16M 176M 13.99M 13.68M 605M 6.14M 4.28M 3.74M 3.45M 3.18M 6M 412M 41.29M 16.26M 202M 16.07M 15.72M 695M
Net income -5.91M -4.12M -3.6M -3.32M -3.06M -5.77M -396M -39.74M -15.65M -194M -15.46M -15.12M -669M -6.11M -4.25M -3.72M -3.43M -3.16M -5.96M -410M -41.05M -16.17M -201M -15.97M -15.62M -691M
Net Debt -96.95K -67.51K -59.07K -54.51K -50.19K -94.61K -6.5M -651K -257K -3.19M -254K -248K -10.96M -237K -165K -145K -133K -123K -232K -15.91M -1.59M -628K -7.8M -620K -607K -26.83M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
17/07/26 A$0.0690 -1.43% 1,674,808
16/07/26 A$0.0700 -5.41% 2,253,176
15/07/26 A$0.0740 -1.33% 530,059
14/07/26 A$0.0750 0.00% 1,035,306
13/07/26 A$0.0750 +2.74% 230,680

Annual profits - Rate of surprise